- Joined
- Mar 1, 2020
I'm not a doctor, even if I do have a doctorate, but here's how I'd look at those numbers. The 6% represents a floor for the number of "actual COVID deaths." The 180k represents an approximate ceiling (could be untested deaths out there). In between we have murky and highly heterogeneous data being mashed together. "Comorbidities" covers a wide range of issues, and the specifics of those issues should matter to how we consider "cause of death." If someone who was on life support after a mortal gunshot wound tested positive, I'd blame the gunshot wound. If someone with beetus and hypertension died, I'd blame it on the bat, because those conditions aren't themselves fatal. My guess is that the comorbidities from a lifetime of pork rinds are going to make up a decent percentage of the 174k. But without doing autopsies on all the dead, I don't think we'll ever know the true number. It's certainly much higher than the 6%, and probably not as high as the official number.
Well, this is the actual data:
Table 3 shows the types of health conditions and contributing causes mentioned in conjunction with deaths involving coronavirus disease 2019 (COVID-19). For 6% of the deaths, COVID-19 was the only cause mentioned. For deaths with conditions or causes in addition to COVID-19, on average, there were 2.6 additional conditions or causes per death. The number of deaths with each condition or cause is shown for all deaths and by age groups.
Updated August 26, 2020
Number of Conditions | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Age Group | ||||||||||
Conditions Contributing to Deaths where COVID-19 was listed on the death certificate1 | ICD–10 codes | All ages | 0–24 years | 25–34 years | 35–44 years | 45–54 years | 55–64 years | 65–74 years | 75–84 years | 85 years and over |
Total COVID-19 deaths2, as of 8/22/2020 | U071 | 161,392 | 330 | 1,241 | 3,228 | 8,501 | 20,295 | 34,334 | 42,587 | 50,867 |
Respiratory diseases | - | - | - | - | - | - | - | - | - | |
Influenza and pneumonia | J09–J18 | 68,004 | 111 | 564 | 1,428 | 3,967 | 9,438 | 15,389 | 18,116 | 18,989 |
Chronic lower respiratory diseases | J40–J47 | 13,780 | 24 | 59 | 139 | 403 | 1,486 | 3,262 | 4,335 | 4,071 |
Adult respiratory distress syndrome | J80 | 21,899 | 59 | 231 | 612 | 1,795 | 3,777 | 5,757 | 5,317 | 4,349 |
Respiratory failure | J96 | 54,803 | 99 | 401 | 1,016 | 2,981 | 7,208 | 12,601 | 15,100 | 15,394 |
Respiratory arrest | R09.2 | 3,282 | 6 | 21 | 64 | 160 | 362 | 667 | 891 | 1,111 |
Other diseases of the respiratory system | J00–J06, J20–J39, J60–J70, J81–J86, J90–J95, J97–J99, U04 | 5,664 | 18 | 45 | 113 | 287 | 708 | 1,193 | 1,531 | 1,769 |
Circulatory diseases | - | - | - | - | - | - | - | - | - | |
Hypertensive diseases | I10–I15 | 35,272 | 14 | 98 | 447 | 1,529 | 4,237 | 7,701 | 9,679 | 11,566 |
Ischemic heart disease | I20–I25 | 18,103 | 2 | 22 | 90 | 420 | 1,656 | 3,695 | 5,461 | 6,755 |
Cardiac arrest | I46 | 20,210 | 46 | 186 | 470 | 1,324 | 2,923 | 4,560 | 5,080 | 5,620 |
Cardiac arrhythmia | I44, I45, I47–I49 | 9,812 | 9 | 22 | 58 | 221 | 709 | 1,748 | 2,873 | 4,172 |
Heart failure | I50 | 10,562 | 4 | 40 | 82 | 272 | 887 | 1,809 | 2,913 | 4,555 |
Cerebrovascular diseases | I60–I69 | 7,653 | 7 | 23 | 80 | 269 | 871 | 1,704 | 2,237 | 2,461 |
Other diseases of the circulatory system | I00–I09, I26–I43, I51, I52, I70–I99 | 8,743 | 39 | 98 | 209 | 504 | 1,129 | 1,928 | 2,157 | 2,679 |
Sepsis | A40–A41 | 14,053 | 31 | 136 | 345 | 1,035 | 2,404 | 3,863 | 3,539 | 2,700 |
Malignant neoplasms | C00–C97 | 7,415 | 24 | 31 | 90 | 277 | 1,006 | 1,932 | 2,250 | 1,805 |
Diabetes | E10–E14 | 25,936 | 41 | 168 | 585 | 1,797 | 4,262 | 6,956 | 6,912 | 5,214 |
Obesity | E65–E68 | 5,614 | 79 | 272 | 630 | 1,017 | 1,399 | 1,317 | 695 | 205 |
Alzheimer disease | G30 | 5,608 | 0 | 0 | 0 | 2 | 50 | 372 | 1,627 | 3,557 |
Vascular and unspecified dementia | F01, F03 | 18,497 | 0 | 0 | 2 | 20 | 283 | 1,713 | 5,409 | 11,070 |
Renal failure | N17–N19 | 13,693 | 14 | 110 | 287 | 909 | 2,001 | 3,477 | 3,597 | 3,296 |
Intentional and unintentional injury, poisoning and other adverse events | S00–T98, V01–X59, X60–X84, X85–Y09, Y10–Y36, Y40–Y89, U01–U03 | 5,133 | 36 | 124 | 176 | 302 | 609 | 1,003 | 1,220 | 1,661 |
All other conditions and causes (residual) | A00–A39, A42–B99, D00–E07, E15–E64, E70–E90, F00, F02, F04–G26, G31–H95, K00–K93, L00–M99, N00–N16, N20–N99, O00–O99, P00–P96, Q00–Q99, R00–R08, R09.0, R09.1, R09.3, R09.8, R10–R99 | 77,990 | 251 | 700 | 1,552 | 4,195 | 10,497 | 18,134 | 20,356 | 22,296 |
It shows exactly what one would expect. The majority of those dying have some combination of old age, hypertension, heart trouble, diabetes, and so forth. This is because COVID-19 preys on people who have Metabolic Syndrome and the associated conditions. That's because these conditions cause endothelial dysfunction and increased ACE2 expression (they make blood vessels behave like they're prematurely aged).
Named by the International Committee on Taxonomy of Viruses (ICTV) as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus, with origin associated with the city of Wuhan, Hubei province, China, spread rapidly worldwide causing thousands of deaths, characterizing the infection as a public health problem of global interest [1,2]. With a high infectivity rate, the coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, reached pandemic proportions [3].
According to the report published by World Health Organization (WHO) on June 1st, the number of confirmed cases reaches 6,057,853 distributed in 216 countries, with emphasis on the European and American continents, with more than two million cases each, together adding up around 82% of infected global number. COVID-19 has already killed more than 371,166 people worldwide, especially among elderly patients and individuals with comorbidities. Currently, the United States (U.S.) has already more than 1,734,040 confirmed cases, but, despite its large number of infected people, it is countries like Spain (29,045 deaths), Italy (33,415 deaths) and The United Kingdom (38,489 deaths) which presented the highest mortality rate, exceeding 10% [4].
The disease evolution and the symptoms vary from asymptomatic patients to severe cases of respiratory failure, which can lead to death [5]. Some risk factors may be associated with the evolution and disease severity. In a study conducted in the U.S., during March 2020, with 1482 patients hospitalized with COVID-19 in fourteen states, 12% of the total were history of comorbidities. Of this total, 49.7% were hypertensive, 48.3% were obese, patients with chronic liver diseases totaled 34.6%, diabetics represented 28.3% and people with cardiovascular diseases were 27.8% [6]. In another study conducted in Wuhan city, China, 191 patients with COVID-19 were followed up, of which 48% had comorbidities such as hypertension (30%), diabetes (19%) and coronary disease (8%) [7]. Until June 1st, 2020, Brazil had 347,398 confirmed cases of COVID-19 with 13,868 deaths associated with comorbidities. Heart disease was the most common comorbidity with total of 7318 deaths, followed by diabetes, kidney disease, neurological disease, pneumopathy, obesity, immunosuppression and asthma, with a total of 5627, 1218, 1159, 1061, 742, 740 and 397 deaths, respectively [8].
In this context, metabolic syndrome (MS) is inserted as a common denominator to these comorbidities, since it is defined as a set of metabolic disorders that include insulin resistance, dyslipidemia, central obesity and hypertension, which are risk factors for the development of type 2 diabetes and cardiovascular diseases [9,10]. In 2017, it was estimated that MS affected 20% of North American population, 25% of European population and approximately 15% of Chinese population [11,12]. In this scenario, the relationship between MS and its comorbidities that aggravate the COVID-19 prognosis cannot be ignored. Also, its presence in different ethnicities and continents places SM as an important risk factor for COVID-19. Thus, this review is aimed at providing overview of metabolic changes associated with MS and its relationship with development and worsening of SARS-CoV-2 infection, as well as to review the proposed drugs for the treatment of these patients. We collated and discussed the available evidences that have emerged so far on the presence of obesity, diabetes, cardiovascular and liver disease in the patients with COVID-19 and proposed therapies.
Diabetes has been identified as the second most common comorbidity among cases of COVID-19. Hypotheses have been raised that this high incidence rate in diabetic patients is directly linked to high gene expression of angiotensin-converting enzyme 2 (ACE2) in their cells, which are used by SARS-CoV-2 to enter human cells, due to treatment with ACE inhibitors and angiotensin II type-I receptor blockers (ARBs) [30]. This would not only increase the risk of these patients to infection but would also make it difficult to control comorbidity during treatment against COVID-19. This relationship is not yet fully understood and further studies are needed to confirm it, since the drug treatment protocols for diabetic patients remain the same for their metabolic dysfunction [31].
If this thing was made in a lab in China as a bioweapon against Americans, they could not have formulated it any better than this. COVID-19 is an American-killer.